The Current Landscape of Modular CAR T Cells.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Current CAR T-cell therapies show success but have limitations like severe adverse events and antigen-negative relapse.
• Unmet clinical needs persist, driving demand for more controllable, programmable, and combinable CAR T-cell treatments for oncology and autoimmunity.

Purpose of the Study:

• To introduce and elaborate on the design principles and advantages of modular CAR T-cell systems.
• To highlight how modularity addresses limitations of direct-targeting CAR T-cells, improving safety, flexibility, and therapeutic potential.

Main Methods:

• Modular CAR T-cells utilize a two-component system: CAR on T-cells binding an adaptor molecule (AM), which in turn binds the tumor-associated antigen (TAA).
• This design separates target recognition from T-cell activation, allowing for adaptable targeting and logic-gated control.
• Key design considerations include CAR architecture, affinity of interactions (CAR-AM and AM-TAA), AM valency, and AM architecture (size).

Main Results:

• Modular CAR T-cells offer enhanced control, flexibility, and safety by decoupling antigen recognition from T-cell activation.
• The adaptor molecule (AM) is swappable, enabling easy multiplexing and logic-based targeting without re-engineering T-cells.
• Design parameters like CAR architecture, binding affinities, AM valency, and size significantly influence system performance, pharmacokinetics, and dosing.

Conclusions:

• Modular CAR T-cell technology presents a promising strategy to overcome limitations of direct-targeting CAR T-cells, potentially mitigating adverse events and antigen escape.
• The system's flexibility in target antigen switching and AM-dosed response modulation could be pivotal for treating heterogeneous cancers.
• Over 30 modular CAR constructs have been developed since 2012, with some progressing to early-phase clinical trials, indicating therapeutic potential.